Your browser is no longer supported. Please, upgrade your browser.
Settings
PYPD [NASD]
PolyPid Ltd.
Index- P/E- EPS (ttm)-2.35 Insider Own13.72% Shs Outstand18.50M Perf Week8.36%
Market Cap155.39M Forward P/E- EPS next Y-2.34 Insider Trans0.00% Shs Float16.17M Perf Month-9.77%
Income-41.80M PEG- EPS next Q-0.53 Inst Own20.10% Short Float0.30% Perf Quarter-11.20%
Sales- P/S- EPS this Y-420.40% Inst Trans- Short Ratio1.59 Perf Half Y-12.99%
Book/sh3.93 P/B2.08 EPS next Y-0.90% ROA- Target Price- Perf Year-45.53%
Cash/sh2.34 P/C3.49 EPS next 5Y- ROE- 52W Range6.95 - 16.50 Perf YTD-17.47%
Dividend- P/FCF- EPS past 5Y-20.50% ROI- 52W High-50.48% Beta-
Dividend %- Quick Ratio16.40 Sales past 5Y- Gross Margin- 52W Low17.55% ATR0.49
Employees57 Current Ratio16.40 Sales Q/Q- Oper. Margin- RSI (14)51.38 Volatility5.32% 5.93%
OptionableNo Debt/Eq0.00 EPS Q/Q-0.80% Profit Margin- Rel Volume1.58 Prev Close7.23
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout- Avg Volume30.16K Price8.17
Recom1.80 SMA202.44% SMA50-6.54% SMA200-18.30% Volume47,502 Change13.00%
Jul-30-21Initiated Cantor Fitzgerald Overweight $24
Nov-24-20Upgrade Raymond James Outperform → Strong Buy
Aug-10-20Initiated Alliance Global Partners Buy $27
Jul-21-20Initiated Raymond James Outperform $23
Jul-21-20Initiated BMO Capital Markets Outperform $30
Jul-21-20Initiated Barclays Overweight $22
Jul-28-21 07:00AM  
Jul-12-21 08:00AM  
Jun-28-21 09:30AM  
Jun-23-21 06:30AM  
Jun-22-21 09:58PM  
Jun-02-21 09:10AM  
May-19-21 12:51PM  
08:00AM  
May-12-21 07:00AM  
06:45AM  
Apr-29-21 07:00AM  
Mar-29-21 08:33AM  
Feb-23-21 07:30AM  
Feb-16-21 07:31AM  
Feb-10-21 07:34AM  
07:00AM  
06:30AM  
Jan-27-21 07:30AM  
Dec-22-20 07:00AM  
Dec-16-20 07:00AM  
Dec-03-20 08:00AM  
Nov-24-20 08:17AM  
Nov-11-20 06:30AM  
Nov-04-20 08:45AM  
Oct-28-20 07:00AM  
Oct-14-20 10:29AM  
Sep-28-20 01:28PM  
Aug-19-20 07:00AM  
Aug-05-20 04:01PM  
Aug-03-20 07:00AM  
Jul-27-20 07:00AM  
Jul-01-20 09:00AM  
Jun-30-20 04:01PM  
Jun-26-20 02:04AM  
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.